Lixte director granted 15,000 RSUs

Holloway Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Holloway Michael Andrew reported acquisition or exercise transactions in this Form 4 filing.

Lixte Biotechnology Holdings director Michael Andrew Holloway received an equity award of 15,000 restricted share units (RSUs). The RSUs were granted under the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan and an applicable RSU agreement.

Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested after the performance conditions in his RSU agreement were satisfied. Following this award, the total reported in his holdings is 40,000 RSUs, consisting of the 15,000 new RSUs and 25,000 previously granted RSUs, all of which have vested.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Holloway Michael Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 40,000 shares (Direct)

Footnotes (2)

1. F1. The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.
2. F2. The total reported in Column 5 includes (i) the 15,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

Key Figures

New RSU grant: 15,000 RSUs Total RSUs after transaction: 40,000 RSUs Previously held RSUs: 25,000 RSUs +1 more

4 metrics

New RSU grant 15,000 RSUs Restricted share units awarded to director Holloway

Total RSUs after transaction 40,000 RSUs Holdings reported following the grant

Previously held RSUs 25,000 RSUs Earlier RSUs included in total holdings

Grant price per share $0.00 per share Equity award under stock incentive plan

Key Terms

restricted share units ("RSUs"), 2020 Stock Incentive Plan, contingent right to receive one share, performance conditions

4 terms

restricted share units ("RSUs") financial

"The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs")."

2020 Stock Incentive Plan financial

"The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan."

contingent right to receive one share financial

"Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service."

performance conditions financial

"The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied."

FAQ

What insider transaction did LIXT director Michael Andrew Holloway report?

Michael Andrew Holloway reported receiving 15,000 restricted share units as an equity award. These RSUs were granted under Lixte Biotechnology Holdings’ 2020 Stock Incentive Plan as compensation, rather than through any open-market purchase or sale of the company’s common stock.

How many LIXT restricted share units does Michael Andrew Holloway hold after this grant?

After the grant, Michael Andrew Holloway’s reported holdings total 40,000 restricted share units. This includes 15,000 newly awarded RSUs from the latest grant and 25,000 earlier RSUs, with all 40,000 RSUs reported as having fully vested under their applicable conditions.

What are the key terms of Michael Andrew Holloway’s 15,000 LIXT RSU award?

The 15,000 RSUs were granted under the company’s 2020 Stock Incentive Plan and a specific RSU agreement. Each RSU entitles him to receive one share of Lixte common stock upon vesting, conditioned on continued service and achievement of designated performance conditions that have already been met.

Were performance conditions involved in Michael Andrew Holloway’s LIXT RSU vesting?

Yes. The 15,000 RSUs vested once performance conditions in his RSU agreement were achieved. The filing states these performance conditions have been satisfied, and vesting remains subject to his continued service, aligning the award with both company results and ongoing director commitment.

Is Michael Andrew Holloway’s LIXT RSU grant an open-market stock purchase?

No. The RSU award is a compensation-related equity grant, not an open-market purchase. It carries a transaction code for grants or awards and shows a price per share of zero, reflecting that the units were issued by the company under its stock incentive plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holloway Michael Andrew

(Last) (First) (Middle)

433 PLAZA REAL, SUITE 275

(Street)

BOCA RATON FLORIDA 33432

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		15,000(1)	A	$0	40,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction involved the Reporting Person's receipt of 15,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable RSU agreement and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 15,000 RSUs vested upon the achievement of the performance conditions set forth in the Reporting Person's RSU agreement, which have been satisfied.

2. The total reported in Column 5 includes (i) the 15,000 newly awarded RSUs, and (ii) 25,000 RSUs, all of which have vested.

	/s/ Michael Holloway	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)